Your browser doesn't support javascript.
loading
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Sadeghi, Leila; Moallemi, Samaneh; Tabatabai, Reza Adl; Esmaeilzadeh, Ali; Ahsani-Nasab, Sara; Ahmadi, Niloofar Eghbal; Bayanolhagh, Saeed; Lolaie, Masoomeh; Narouei, Arsalan; SeyedAlinaghi, SeyedAhmad; Mohraz, Minoo.
Afiliación
  • Sadeghi L; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Moallemi S; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Tabatabai RA; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Esmaeilzadeh A; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahsani-Nasab S; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadi NE; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Bayanolhagh S; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Lolaie M; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Narouei A; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • SeyedAlinaghi S; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohraz M; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Infect Disord Drug Targets ; 18(3): 207-213, 2018.
Article en En | MEDLINE | ID: mdl-29308748
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Zidovudina / Infecciones por VIH / VIH-1 / Inhibidores de la Transcriptasa Inversa / Lamivudine / Benzoxazinas / Inmunidad Celular Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Infect Disord Drug Targets Asunto de la revista: DOENCAS TRANSMISSIVEIS / TERAPIA POR MEDICAMENTOS Año: 2018 Tipo del documento: Article País de afiliación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Zidovudina / Infecciones por VIH / VIH-1 / Inhibidores de la Transcriptasa Inversa / Lamivudine / Benzoxazinas / Inmunidad Celular Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Infect Disord Drug Targets Asunto de la revista: DOENCAS TRANSMISSIVEIS / TERAPIA POR MEDICAMENTOS Año: 2018 Tipo del documento: Article País de afiliación: Irán